The Board of Directors of Dicot Pharma AB intends to resolve on a rights issue of units, consisting of shares and warrants, corresponding to approximately SEK 210 million to finance the planned Phase IIb study with the drug candidate LIB-01.

The resolution on the Issue is intended to be made pursuant to the authorization proposed to the Annual General Meeting on May 6, 2026. The Issue, including complete terms and conditions, is expected to be resolved by the Board of Directors around May 8, 2026. The Issue is secured to 80 percent, corresponding to SEK 168 million, through subscription undertakings and guarantee commitments from existing shareholders as well as guarantee commitments from Schonfeld Global Master Fund LP, Anavio Capital Partners LLP and Vator Securities.

Read the full release here.